GSK, SK Bioscience start late-stage trials of COVID-19 vaccine

SK Bioscience Co

31/08/2021 07:07

Aug 31 (Reuters) - Britain's GlaxoSmithKline  GSK.L  and
South Korea's SK Bioscience  302440.KS  said on Tuesday the
drugmakers have begun a late-stage clinical study of SK's
COVID-19 vaccine candidate in combination with GSK's pandemic
vaccine booster.

 (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak
Dasgupta)
 ((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793))